Penumbra (PEN) Current Deferred Revenue (2022)
Penumbra (PEN) posted quarterly Current Deferred Revenue of $9.6 million for Q2 2022, up 28.0% quarter-over-quarter from $7.5 million in Q1 2022.
Penumbra (PEN) Current Deferred Revenue (2022) Analysis & Trends
Penumbra (PEN) has reported Current Deferred Revenue for 1 consecutive years, with $9.6 million the latest figure, recorded in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.24 Bn | 193.64 Bn | 7.27 Bn |
| 2 | Stryker | 128.63 Bn | 125.15 Bn | 4.50 Bn |
| 3 | Medtronic | 119.19 Bn | 109.97 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.51 Bn | 72.97 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.85 Bn | 1.35 Bn |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 34.01 Bn | 31.90 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn |
| 9 | Steris | 23.14 Bn | 22.65 Bn | 684.20 Mn |
| 10 | Penumbra | 12.80 Bn | 12.14 Bn | 264.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 9.60 Mn |
| Mar 31, 2022 | 7.50 Mn |